A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias.

Trial Profile

A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2012

At a glance

  • Drugs SGI 1776 (Primary)
  • Indications Leukaemia
  • Focus Adverse reactions
  • Sponsors Astex Pharmaceuticals
  • Most Recent Events

    • 28 Nov 2011 Company added in the association field and additional lead trial center identified as reported by ClinicalTrials.gov.
    • 18 Nov 2010 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 18 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top